Your browser doesn't support javascript.
loading
Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial.
Tricou, Vianney; Sáez-Llorens, Xavier; Yu, Delia; Rivera, Luis; Jimeno, José; Villarreal, Ana Cecilia; Dato, Epiphany; Saldaña de Suman, Onix; Montenegro, Nathali; DeAntonio, Rodrigo; Mazara, Sonia; Vargas, Maria; Mendoza, Debbie; Rauscher, Martina; Brose, Manja; Lefevre, Inge; Tuboi, Suely; Borkowski, Astrid; Wallace, Derek.
Affiliation
  • Tricou V; Takeda Pharmaceuticals International, Zurich, Switzerland. Electronic address: vianney.tricou@takeda.com.
  • Sáez-Llorens X; Hospital del Niño Dr José Renán Esquivel, Panama City, Panama; Sistema Nacional de Investigación, Secretaría Nacional de Ciencia, Tecnología e Innovación, Panama City, Panama.
  • Yu D; De La Salle Health Sciences Institute, Cavite, Philippines.
  • Rivera L; Hospital Universitario Maternidad Nuestra Señora de la Altagracia, Santo Domingo, Dominican Republic.
  • Jimeno J; Centro de Vacunación Internacional (Cevaxin), Panama City, Panama.
  • Villarreal AC; Centro de Vacunación Internacional (Cevaxin), Panama City, Panama.
  • Dato E; De La Salle Health Sciences Institute, Cavite, Philippines.
  • Saldaña de Suman O; Centro de Vacunación Internacional (Cevaxin), Panama City, Panama.
  • Montenegro N; Centro de Vacunación Internacional (Cevaxin), Panama City, Panama.
  • DeAntonio R; Sistema Nacional de Investigación, Secretaría Nacional de Ciencia, Tecnología e Innovación, Panama City, Panama; Centro de Vacunación Internacional (Cevaxin), Panama City, Panama.
  • Mazara S; Hospital Universitario Maternidad Nuestra Señora de la Altagracia, Santo Domingo, Dominican Republic.
  • Vargas M; Hospital Universitario Maternidad Nuestra Señora de la Altagracia, Santo Domingo, Dominican Republic.
  • Mendoza D; Takeda Vaccines, Singapore, Singapore.
  • Rauscher M; Takeda Pharmaceuticals International, Zurich, Switzerland.
  • Brose M; Takeda Pharmaceuticals International, Zurich, Switzerland.
  • Lefevre I; Takeda Pharmaceuticals International, Zurich, Switzerland.
  • Tuboi S; Takeda Pharmaceuticals, Rio de Janeiro, Brazil.
  • Borkowski A; Takeda Pharmaceuticals International, Zurich, Switzerland.
  • Wallace D; Takeda Vaccines, Cambridge, MA, USA.
Lancet ; 395(10234): 1434-1443, 2020 05 02.
Article in En | MEDLINE | ID: mdl-32197107
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Virus / Dengue Vaccines / Immunogenicity, Vaccine Type of study: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Country/Region as subject: America central / Asia / Panama / Republica dominicana Language: En Journal: Lancet Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dengue / Dengue Virus / Dengue Vaccines / Immunogenicity, Vaccine Type of study: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Limits: Adolescent / Child / Child, preschool / Female / Humans / Male Country/Region as subject: America central / Asia / Panama / Republica dominicana Language: En Journal: Lancet Year: 2020 Type: Article